NASDAQ:ANIK

Anika Therapeutics (ANIK) Stock Forecast, Price & News

$27.27

+0.55 (+2.06%)

(As of 06/2/2023 ET)

Compare

Today's Range: $26.61
▼
$27.51
50-Day Range: $25.16
▼
$28.86
52-Week Range: $20.12
▼
$32.51

Volume: 81,054 shs
Average Volume: 63,064 shs
Market Capitalization: $402.51 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $29.50

Anika Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 8.2% Upside
$29.50 Price Target
Short Interest: Bearish
3.04% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.83
Upright™ Environmental Score
News Sentiment: 1.12
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.13) to ($0.73) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

894th out of 983 stocks

Surgical & Medical Instruments Industry

87th out of 97 stocks

1.0

Analyst's Opinion

Consensus Rating
Anika Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $29.50, Anika Therapeutics has a forecasted upside of 8.2% from its current price of $27.27.
Amount of Analyst Coverage
Anika Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.04% of the outstanding shares of Anika Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Anika Therapeutics has a short interest ratio ("days to cover") of 5.4.
Change versus previous month
Short interest in Anika Therapeutics has recently increased by 3.82%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Anika Therapeutics does not currently pay a dividend.
Dividend Growth
Anika Therapeutics does not have a long track record of dividend growth.

3.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Anika Therapeutics has received a 45.27% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Nonwoven medical wipes" products. See details.
Environmental Sustainability
The Environmental Impact score for Anika Therapeutics is -1.83.

3.4

News and Social Media Coverage

News Sentiment
Anika Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Anika Therapeutics this week, compared to 3 articles on an average week.
Search Interest
1 people have searched for ANIK on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Anika Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.03% of the stock of Anika Therapeutics is held by insiders.
Percentage Held by Institutions
91.57% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Anika Therapeutics are expected to grow in the coming year, from ($1.13) to ($0.73) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Anika Therapeutics is -17.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Anika Therapeutics is -17.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Anika Therapeutics has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Anika Therapeutics (NASDAQ:ANIK) Stock

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ANIK Stock News Headlines

May 31, 2023 | msn.com

Stephens & Co. Reiterates Anika Therapeutics (ANIK) Equal-Weight Recommendation

May 30, 2023 | finance.yahoo.com

Anika Completes Enrollment in Hyalofast® U.S. Pivotal Phase III Study Achieving Key Milestone

June 3, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 25, 2023 | americanbankingnews.com

Assure (NASDAQ:IONM) vs. Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Review

May 19, 2023 | americanbankingnews.com

Anika Therapeutics (NASDAQ:ANIK) Now Covered by Analysts at StockNews.com

May 17, 2023 | marketwatch.com

Hemostatic Agents Market Research | 2023-2030

May 16, 2023 | finance.yahoo.com

Global Osteoarthritis Therapeutics Market to Reach $15.8 Billion by 2030

May 16, 2023 | seekingalpha.com

ANIK Anika Therapeutics, Inc.

June 3, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

May 16, 2023 | americanbankingnews.com

Short Interest in Anika Therapeutics, Inc. (NASDAQ:ANIK) Decreases By 6.1%

May 15, 2023 | marketwatch.com

Injectable Hyaluronic Acid Fillers Market: 2023-2030 Revenue

May 14, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Anika Therapeutics, Inc. (NASDAQ:ANIK) Reduced by Barrington Research

May 12, 2023 | marketwatch.com

Hyaluronic Acid Products Market Price & News with Size Forecast

May 11, 2023 | marketwatch.com

2023 Arthritis Pain Injection Drug Market Size and Competitor Analysis in Medical Care Sector | with [104 Pages] and Forecast till 2031

May 11, 2023 | markets.businessinsider.com

Barrington Keeps Their Hold Rating on Anika Therapeutics (ANIK)

May 11, 2023 | marketwatch.com

2023-2029 Adhesion Barrier Gel Market Growth Prospects and Countries Analysis | with 85 Pages

May 10, 2023 | finanznachrichten.de

Anika Therapeutics Inc.: Anika Reports First Quarter 2023 Financial Results

May 9, 2023 | msn.com

Recap: Anika Therapeutics Q1 Earnings

May 9, 2023 | finance.yahoo.com

Anika Therapeutics (ANIK) Reports Q1 Loss, Tops Revenue Estimates

May 9, 2023 | finance.yahoo.com

Anika Reports First Quarter 2023 Financial Results

May 5, 2023 | marketwatch.com

Biomaterials Market Analysis and Forecast to 2031

May 2, 2023 | marketwatch.com

2023-2030 Hyaluronic Acid (HA) Raw Material Market Growth Developments with Latest Updates

April 29, 2023 | marketwatch.com

Cross-linked Hyaluronic Acid Market Demand by 2031

April 28, 2023 | marketwatch.com

8-K: Anika Therapeutics, Inc.

April 28, 2023 | marketwatch.com

Biological Bone Repair Materials Market Complete Overview till 2030

April 27, 2023 | marketwatch.com

Biomaterials Market Overview and Scope By 2030

April 26, 2023 | marketwatch.com

Orthopedic Hyaluronic Acid Market Complete Overview till 2031

See More Headlines

ANIK Price History

30 days | 90 days | 365 days | Advanced Chart

ANIK Company Calendar

Last Earnings: 3/06/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: Health Care Supplies
Sector: Medical
Current Symbol: NASDAQ:ANIK
CUSIP: 03525510
CIK: 898437
Web: www.anikatherapeutics.com
Phone: (781) 457-9000
Fax: 781-305-9720
Employees: 297
Year Founded: 1992

Price Target and Rating

Average Stock Price Forecast: $29.50
High Stock Price Forecast: $31.00
Low Stock Price Forecast: $28.00
Forecasted Upside/Downside: +8.2%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,860,000.00
Net Margins: -14.15%
Pretax Margin: -17.18%
Return on Equity: -3.77%
Return on Assets: -3.08%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.59
Quick Ratio: 4.15

Sales & Book Value

Annual Sales: $156.24 million
Price / Sales: 2.58
Cash Flow: $0.52 per share
Price / Cash Flow: 52.58
Book Value: $18.81 per share
Price / Book: 1.45

Miscellaneous

Outstanding Shares: 14,760,000
Free Float: 14,310,000
Market Cap: $402.51 million
Optionable: Optionable
Beta: 0.84

Social Links

Key Executives

Cheryl Renee Blanchard
President, Chief Executive Officer & Director

Anne Nunes
Vice President-Operations

Michael L. Levitz
Chief Financial Officer, Treasurer & EVP

Mira Leiwant
VP-Quality, Regulatory & Clinical Affairs

Steven W. Ek
Vice President-Research & Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ANIK Stock - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ANIK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANIK, but not buy additional shares or sell existing shares.
View ANIK analyst ratings or view top-rated stocks.
What is Anika Therapeutics' stock price forecast for 2023?: 2 brokers have issued 12 month target prices for Anika Therapeutics' stock. Their ANIK share price forecasts range from $28.00 to $31.00. On average, they predict the company's stock price to reach $29.50 in the next twelve months. This suggests a possible upside of 8.2% from the stock's current price.
View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts.
How have ANIK shares performed in 2023?: Anika Therapeutics' stock was trading at $29.60 at the start of the year. Since then, ANIK stock has decreased by 7.9% and is now trading at $27.27.
View the best growth stocks for 2023 here.
When is Anika Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our ANIK earnings forecast.
How were Anika Therapeutics' earnings last quarter?: Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings data on Monday, March, 6th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.06. The biotechnology company had revenue of $39.62 million for the quarter, compared to the consensus estimate of $38.32 million. Anika Therapeutics had a negative net margin of 14.15% and a negative trailing twelve-month return on equity of 3.77%.
What ETFs hold Anika Therapeutics' stock?: ETFs with the largest weight of Anika Therapeutics (NASDAQ:ANIK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Royce Quant Small-Cap Quality Value ETF (SQLV), Syntax Stratified SmallCap ETF (SSLY), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).Vanguard U.S. Minimum Volatility ETF (VFMV) and
What guidance has Anika Therapeutics issued on next quarter's earnings?: Anika Therapeutics updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $158.00 million-$163.00 million, compared to the consensus revenue estimate of $161.06 million.

What other stocks do shareholders of Anika Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).
What is Anika Therapeutics' stock symbol?: Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."
Who are Anika Therapeutics' major shareholders?: Anika Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.67%), Trigran Investments Inc. (10.85%), Dimensional Fund Advisors LP (6.64%), State Street Corp (6.23%), Caligan Partners LP (4.85%) and Renaissance Technologies LLC (3.90%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, James Loerop, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends.
How do I buy shares of Anika Therapeutics?: Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Anika Therapeutics' stock price today?: One share of ANIK stock can currently be purchased for approximately $27.27.
How much money does Anika Therapeutics make?: Anika Therapeutics (NASDAQ:ANIK) has a market capitalization of $402.51 million and generates $156.24 million in revenue each year. The biotechnology company earns $-14,860,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.
How many employees does Anika Therapeutics have?: The company employs 297 workers across the globe.
How can I contact Anika Therapeutics?: Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.anikatherapeutics.com. The biotechnology company can be reached via phone at (781) 457-9000, via email at investorrelations@anikatherapeutics.com, or via fax at 781-305-9720.

This page (NASDAQ:ANIK) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial